Nasopharyngeal Neoplasms
Information
- Disease name
- Nasopharyngeal Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03700476 | Active, not recruiting | Phase 3 | Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | December 21, 2018 | January 2025 |
| NCT03840421 | Active, not recruiting | Phase 3 | GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | April 3, 2019 | December 31, 2028 |
| NCT03427827 | Active, not recruiting | Phase 3 | PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | July 2, 2018 | February 2026 |
| NCT00342147 | Completed | Family Study of Head and Neck Cancers in Taiwan | November 7, 1995 | June 5, 2020 | |
| NCT00078494 | Completed | Phase 1 | Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | February 2004 | May 2006 |
| NCT00436293 | Completed | Phase 2 | Taxotere + Cisplatin in Nasopharyngeal Carcinoma | December 2002 | March 2010 |
| NCT00436800 | Completed | Phase 2 | Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma | March 2005 | October 2008 |
| NCT00565448 | Completed | Phase 2 | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | November 2007 | January 2012 |
| NCT02444949 | Completed | Phase 2 | A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma | June 2014 | December 2019 |
| NCT02505139 | Completed | The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients | December 2014 | August 2016 | |
| NCT00188877 | Completed | Phase 2 | Intensity Modulated Radiation Therapy for Head and Neck Cancer | June 2003 | June 2019 |
| NCT02269943 | Completed | Phase 2 | Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | February 13, 2015 | April 20, 2017 |
| NCT02360501 | Completed | Phase 2 | Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | January 2008 | April 2016 |
| NCT02611960 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | April 18, 2016 | September 30, 2022 |
| NCT00630149 | Completed | Phase 2 | Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy | November 2007 | January 2012 |
| NCT00747799 | Completed | Phase 2 | Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | January 2009 | November 2011 |
| NCT01256853 | Completed | Phase 1 | Modified Vaccinia Ankara (MVA) Vaccine Study | September 2006 | September 2010 |
| NCT01528618 | Completed | Phase 3 | Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma | February 21, 2012 | December 20, 2020 |
| NCT03180476 | Completed | Phase 2 | Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma | April 1, 2017 | April 1, 2020 |
| NCT01797900 | Completed | Phase 2 | The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | March 2013 | September 2014 |
| NCT00123864 | Completed | Phase 1/Phase 2 | Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function | January 2000 | |
| NCT03010813 | Completed | N/A | A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery | December 2016 | October 2017 |
| NCT04446663 | Not yet recruiting | Phase 2 | Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma | July 15, 2020 | December 15, 2024 |
| NCT05807880 | Not yet recruiting | Phase 2 | Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma | October 1, 2023 | October 1, 2025 |
| NCT04870905 | Not yet recruiting | Phase 2 | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | March 1, 2023 | May 1, 2026 |
| NCT06019130 | Recruiting | Phase 2 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | January 10, 2023 | January 9, 2028 |
| NCT02211677 | Recruiting | Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma | August 2014 | December 2024 | |
| NCT03837808 | Recruiting | Phase 3 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | April 11, 2019 | February 11, 2024 |
| NCT03769467 | Terminated | Phase 1/Phase 2 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | February 19, 2019 | August 19, 2021 |
| NCT02874651 | Terminated | Phase 2 | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy | October 2016 | August 27, 2020 |
| NCT00563862 | Terminated | N/A | Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) | July 1999 | June 2007 |
| NCT00393224 | Terminated | Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families | July 5, 2005 | June 2, 2020 | |
| NCT01257100 | Terminated | Environmental and Genetic Determinants of NPC | December 8, 2010 | June 2, 2020 | |
| NCT02980315 | Unknown status | Phase 1/Phase 2 | A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application | November 2016 | December 2017 |
| NCT02250599 | Unknown status | Phase 2 | Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | August 2014 | December 2016 |
| NCT03093649 | Unknown status | N/A | Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma | July 2017 | May 2019 |
| NCT01762514 | Unknown status | Phase 2 | A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens | January 2013 | December 2019 |
| NCT01735409 | Unknown status | Phase 1/Phase 2 | Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma | November 2012 | June 2014 |
| NCT03619824 | Unknown status | Phase 2 | PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma | January 2019 | March 2024 |
| NCT00363831 | Unknown status | Phase 2 | Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma | July 2006 | |
| NCT00577057 | Unknown status | N/A | Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer | September 2006 | August 2013 |
| NCT03854838 | Unknown status | Phase 2 | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | May 1, 2019 | February 1, 2023 |
| NCT00563927 | Unknown status | N/A | Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) | March 1999 | October 2009 |
| NCT02627807 | Unknown status | N/A | Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma | December 2015 | December 2022 |
| NCT02456506 | Unknown status | N/A | Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. | June 2015 | March 2023 |
| NCT02729324 | Unknown status | Phase 2 | Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT | April 2016 | June 2017 |
| NCT02735317 | Unknown status | Phase 2 | Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT | April 2016 | June 2017 |
| NCT02902432 | Unknown status | Phase 2 | A Trial of Endostar in Patients With Carcinoma of the Head and Neck | June 2016 | January 2019 |
| NCT02945878 | Unknown status | Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma | October 2016 | May 2018 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009303